Carmed Pharmaceuticals Gains CityBiz Coverage as Company Expands U.S. Presence

Carmed Pharmaceuticals, a Turkey-based science-driven company that develops standardized carvacrol-based formulations, has been featured in a CityBiz executive Q&A with founder Mustafa Can as the company accelerates its expansion into the United States market. The interview explores Can’s transition from a maritime career to founding a research-focused pharmaceutical company and details Carmed’s formulation philosophy, research initiatives, and U.S. market strategy.

The CityBiz feature highlights Carmed’s emphasis on “rational synergy,” which involves combining multiple bioactive compounds within standardized formulations designed for consistency, reproducibility, and analytical validation. Can explained that a personal interest in longevity and preventive wellness led him to years of independent research before formally establishing the company.

This editorial placement comes as Carmed builds awareness in the U.S. through a multi-channel distribution strategy. Several Carmed formulations are now available on OneLavi.com, including Vacrol® Kids Spray, S-Mix®, Vacrol® Capsule, and Vacrol-M® Capsule. Vacrol® Kids Spray and S-Mix® are gluten-free, non-GMO, sugar-free, preservative-free, and halal-certified. The company has also announced plans to expand availability through Amazon as part of its broader U.S. rollout.

“We believe educational visibility and accessibility must develop together,” said Ceren Can, Global Brand Director of Carmed Pharmaceuticals. “The CityBiz feature helps communicate the philosophy behind Carmed while platforms like OneLavi and Amazon help make our formulations more accessible to consumers in the United States.”

The CityBiz interview also discusses Carmed’s commitment to scientific collaboration. The company works with physicians, researchers, laboratories, and academic partners to support formulation development and evaluation. In January 2026, research involving Carmed formulations Vacrol® and S-Mix® was published in the peer-reviewed journal Plants, where formulations were examined in preclinical laboratory and in ovo models. The company emphasizes that this research is not presented as evidence that its consumer products diagnose, treat, cure, or prevent any disease.

Carmed’s U.S. strategy focuses on long-term brand development through scientific credibility, regulatory alignment, educational visibility, and expanded consumer accessibility. “Our goal is to build a company that is known for consistency, credibility, and a long-term commitment to research-driven development,” Can said in the CityBiz feature.

The full CityBiz Q&A with Mustafa Can is available here.

This news story relied on content distributed by Newsworthy.ai. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Carmed Pharmaceuticals Gains CityBiz Coverage as Company Expands U.S. Presence.

The post Carmed Pharmaceuticals Gains CityBiz Coverage as Company Expands U.S. Presence appeared first on citybuzz.